Although there is no general impact of cytotoxic dose intensity on outcome expected with the regimens used in this study, intensified daunorubicin in AML induction (90 mg/m2 vs 60 mg/m2) has been shown in a post-hoc analysis to provide some benefit to patients with FLT3-ITD [31, 32]. The gene discussed is FLT3; the disease is acute myeloid leukemia.